Verve Therapeutics, Inc.
201 Brookline Avenue
Suite 601
Cambridge, MA 02215
United States
617 603 0070
https://www.vervetx.com
版塊: Healthcare
行業: Biotechnology
全職員工: 255
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Burt A. Adelman M.D. | Co-Founder & Independent Chairman of the Board | 87.55k | 無 | 1952 |
| Mr. Andrew D. Ashe J.D. | President, COO & General Counsel | 703.85k | 無 | 1967 |
| Dr. Andrew Bellinger M.D., Ph.D. | Chief Scientific Officer | 703.85k | 無 | 1979 |
| Dr. Kiran Musunuru M.D., M.P.H., Ph.D. | Co-Founder | 無 | 無 | 無 |
| Dr. J. Keith Joung M.D., Ph.D. | Co-Founder | 無 | 無 | 無 |
| Dr. Anthony Philippakis M.D., Ph.D. | Co-Founder & Scientific Advisory Board Member | 7.97k | 無 | 無 |
| Dr. Barry S. Ticho FACC, M.D., Ph.D. | Co-Founder | 無 | 無 | 1961 |
| Mr. Issi Rozen M.B.A. | Co-Founder & Strategic Advisor | 無 | 無 | 無 |
| Ms. Allison Dorval | CFO & Principal Accounting Officer | 260.93k | 無 | 1976 |
| Ms. Joan Nickerson M.B.A. | Chief Administrative Officer | 無 | 無 | 1969 |
描述
Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
公司管治
截至 2024年4月1日 止，Verve Therapeutics, Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：7；董事會：7；股東權利：8；現金賠償：8。
